|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Fibromyalgia - Substantial Growth Opportunity for SNRI Antidepressants
Datamonitor, March 2004, Pages: 113
Introduction
Fibromyalgia is a relatively common chronic pain syndrome, affecting around 2% of the population. This little understood market suffers from high unmet need both at the level of drug research and current clinical practice. Several leading industry players, including Pfizer, Eli Lilly, and Wyeth, have expressed an interest in this niche thus highlighting the commercial opportunity it offers.
Scope
-Quantitative treatment data from over 260 physicians from the US, Japan, France, Germany, Italy, Spain and the UK
-Analysis of epidemiology, assessment and referral patterns, first- to third-line treatments, and unmet market needs
-Discussion of the R&D drug pipeline for fibromyalgia, including analysis of duloxetine, pregabalin, and milnacipran
-Coverage of the hot topics including the potential of SNRI antidepressants and the need to push regulatory agencies to recognize fibromyalgia
Report Highlights
Fibromyalgia is a common syndrome that is substantially under served by the medical profession and the pharmaceutical industry. The challenge facing investors is to provide improved understanding of the biologic and physiologic processes responsible for the symptoms, in order to develop better pain medications that can improve quality of life.
The biggest commercial opportunity is for manufacturers of serotonin and noradrenaline reuptake inhibitors (SNRIs). Forest’s SNRI milnacipran is the closest to entering the market, although competition from Eli Lilly and Wyeth can be expected in the near future.
Companies aiming to enter the fibromyalgia market need to push regulatory agencies to recognize the condition as a single clinical entity. Until this is achieved, companies will be unable to gain labeling for fibromyalgia.
Reasons to Purchase
Forecast product sales by understanding key aspects of fibromyalgia epidemiology, diagnosis, and treatment
Gain a better understanding of the challenges faced by future players in the fibromyalgia market
Predict trends in the treatment of fibromyalgia and how to capitalize on forthcoming changes in treatment practice
Customers who bought this item also bought
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Commercial Insight: Antidepressants - Sliding SSRI Revenues Inevitable
Anxiety Disorders: The New Focus for Antidepressants
High-Growth Diagnostic Tests Markets
Market Dynamics 2001: Antidepressants - Absorbing the Impact of Generic Prozac
United States antidepressants market by number of prescriptions and percent growth for 2000 to 2003
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
|
|
|
|
